Human plasma fibronectin potentiates the mitogenic activity of platelet-derived growth factor and complements its wound healing effects

Wound Repair and Regeneration

Volumn 11, Issue 1, 2003, Pages 79-89

  Larivière, Benoît ^a   Rouleau, Michèle ^a   Picard, Sylvain ^a   Beaulieu, André D ^a,b  

^a LAVAL UNIVERSITY   (Canada)

^b UNIVERSITÉ LAVAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

FIBRONECTIN; INTEGRIN; RECOMBINANT PLATELET DERIVED GROWTH FACTOR BB;

ADOLESCENT; ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL ADHESION; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED DRUG RELEASE; DRUG DELIVERY SYSTEM; DRUG EFFECT; DRUG FORMULATION; HUMAN; IMMUNOFLUORESCENCE; MITOGENESIS; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; RABBIT; SKIN INJURY; WOUND HEALING;

ADMINISTRATION, TOPICAL; ANGIOGENESIS INDUCING AGENTS; ANIMALS; DELAYED-ACTION PREPARATIONS; DISEASE MODELS, ANIMAL; DRUG THERAPY, COMBINATION; FIBRONECTINS; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; MITOGENS; PLATELET-DERIVED GROWTH FACTOR; RABBITS; SKIN; WOUND HEALING; WOUNDS, PENETRATING;

EID: 0037282424     PISSN: 10671927     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1524-475X.2003.11112.x     Document Type: Article

References (41)

1. Potts JR, Campbell ID. Fibronectin structure and assembly. Curr Opin Cell Biol 1994;6:648-55.
2. Singer AJ, Clark RAF. Cutaneous wound healing. New Eng J Med 1999;341:738-46.
3. Grinnell F. Fibronectin and wound healing. J Cell Biochem 1984;26:107-16.
4. Clark RAF. Fibronectin matrix deposition and fibronectin receptor expression in healing and normal skin. J Invest Dermatol 1990;94:128S-34S.
5. Bennett NT, Schultz GS. Growth factors and wound healing: Part II. Role in normal and chronic wound healing. Am J Surg 1993;166:74-81.
6. Giancotti F, Ruoslahti E. Integrin signaling. Science 1999;285:1028-32.
7. Gailit J, Clark RAF. Wound repair in the context of extracellular matrix. Curr Opin Cell Biol 1994;6:717-25.
8. 1 phase cell-cycle progression. Curr Opin Gen Dev 2001;11:48-53.
9. Horowitz B, Bonomo R, Prince AM, Chin SN, Brotman B, Shulman RW. Solvent/detergent treated plasma: a virus-inactivated substitute for fresh frozen plasma. Blood 1992;79:826-31.
10. Horowitz B, Chang MDY. Preparation of fibronectin for therapeutic administration. In: Mosher DF, editor. Fibronectin. San Diego: Academic Press, 1989:441-55.
11. Alexander DM, Hesson T, Mannarino A, Cable M, Dalie BL. Isolation and purification of a biologically active human platelet-derived growth factor BB expressed in Escherichia coli. Prot Expr Purif 1992;3:204-11.
12. Hoppe J, Weich HA, Eichner W. Preparation of biologically active platelet-derived growth factor type BB from a fusion protein expressed in Escherichia coli. Biochemistry 1989;28:2956-60.
13. Bronaugh RL. In vitro viable skin model. In: Borchardt RT, Smith PL, Wilson G, editors. Models for assessing drug absorption and metabolism. New York Plenum Press, 1996:375-86.
14. Mustoe TA, Pierce GF, Morishima C, Deuel TF. Growth factor-induced acceleration of tissue repair through direct and inductive activities in a rabbit dermal ulcer model. J Clin Invest 1991;87:694-703.
15. Pierce GF, Mustoe TA, Senior RM, Reed J, Griffin GL, Thomason A, Deuel TF. In vivo incisional wound healing augmented by platelet-derived growth factor and recombinant c-sis gene homodimeric proteins. J Exp Med 1988;167:974-87.
16. Sakai T, Johnson KJ, Murozono M, Sakai K, Magnuson MA, Wieloch T, Cronberg T, Isshiki A, Erickson HP, Fassler R. Plasma fibronectin supports neuronal survival and reduces brain injury following transient focal cerebral ischemia but is not essential for skin-wound healing and hemostasis. Nature Med 2001;7:324-30.
17. Falcone PA, Bonaventura M, Turner DC, Fromm D. The effect of exogenous fibronectin on wound breaking strength. Plast Reconstruct Surg 1984;74:809-12.
18. Cheng CY, Martin DE, Leggett CG, Reece MC, Reese AC. Fibronectin enhances healing of excised wounds in rats. Arch Dermatol 1988;124:221-5.
19. Jo JS, Hong SB, Shin HI, Choi JY. Homologous fibronectin enhances healing of excised wounds in rats. J Kor Med Sci 1991;6:197-205.
20. Scheel G, Rhahfoth B, Franke J, Grau P. Acceleration of wound healing by local application of fibronectin. Arch Orthop Trauma Surg 1991;110:284-7.
21. Puolakkainen PA, Twardzik DR, Ranchalis JE, Pankey SC, Reed MJ, Gombotz WR. The enhancement in wound healing by transforming growth factor-β1 (TGF-β1) depends on the topical delivery system. J Surg Res 1995;58:321-9.
22. Smith-Thomas L, Richardson P, Parsons MA, Rennie IG, Benson M, MacNeil S. Additive effects of extracellular matrix proteins and platelet derived mitogens on human retinal pigment epithelial cell proliferation and contraction. Curr Eye Res 1996;15:739-48.
23. Sechler JL, Schwarzbauer JE. Control of cell cycle progression by fibronectin matrix architecture. J Biol Chem 1998;273:25533-6.
24. Sottile J, Hocking DC, Swiatek PJ. Fibronectin matrix assembly enhances adhesion-dependent cell growth. J Cell Sci 1998;111:2933-43.
25. Schwartz MA, Baron V. Interactions between mitogenic stimuli, or, a thousand and one connections. Curr Opin Cell Biol 1999;11:197-202.
26. Miyamoto S, Teramoto H, Gutkind JS, Yamada KM. Integrins can collaborate with growth factors for phosphorylation of receptor tyrosine kinases and MAP kinase activation: role of integrin aggregation and occupancy of receptors. J Cell Biol 1996;135:1633-42.
27. Schneller M, Vuori K, Ruoslahti E. αvβ3 integrin associates with activated insulin and PDGFβ receptors and potentiates the biological activity of PDGF. EMBO J 1997;16:5600-7.
28. McNamee HP, Ingber DE, Schwartz MA, Adhesion to fibronectin stimulates inositol lipid synthesis and enhances PDGF-induced inositol lipid breakdown. J Cell Biol 1993;121:673-8.
29. DeMali KA, Balciunaite E, Kazlauskas A. Integrins enhance platelet-derived growth factor (PDGF)-dependent responses by altering the signal relay enzymes that are recruited to the PDGF β receptor. J Biol Chem 1999;274:19551-8.
30. Asthagiri AR, Reinhart CA, Horwitz AF, Lauffenburger DA. The role of transient ERK2 signals in fibronectin- and insulin-mediated DNA synthesis. J Cell Sci 2000;113:4499-510.
31. Kuwada SK, Li X. Integrin α5/β1 mediates fibronectin-dependent epithelial cell proliferation through epidermal growth factor receptor activation. Mol Biol Cell 2000;11:2485-96.
32. Allen-Hoffmann BL, Crankshaw CL, Mosher DF. Transforming growth factor β increases cell surface binding and assembly of exogenous (plasma) fibronectin by normal human fibroblasts. Mol Cell Biol 1988;8:4234-42.
33. Dalton SL, Marcantonio EE, Assoian RK. Cell attachment controls fibronectin and α5β1 integrin levels in fibroblasts. J Biol Chem 1992;267:8186-91.
34. Gailit J, Xu J, Bueller H, Clark RA. Platelet-derived growth factor and inflammatory cytokines have differential effects on the expression of integrins α1β1 and α5β1 by human dermal fibroblasts in vitro. J Cell Physiol 1996;169:281-9.
35. Pickering JG, Chow LH, Li S, Rogers KA, Rocnik EF, Zhong R, Chan BMC. α5β1 integrin expression and luminal edge fibronectin matrix assembly by smooth muscle cells after arterial injury. Am J Pathol 2000;156:453-65.
36. García AJ, Boettiger D. Integrin-fibronectin interactions at the cell-material interface: initial integrin binding and signaling. Biomaterials 1999;20:2427-33.
37. Clark RAF, McCoy GA, Folkvord JM, McPherson JM, TGF-β1 stimulates cultured human fibroblasts to proliferate and produce tissue-like fibroplasia: a fibronectin matrix-dependent event. J Cell Physiol 1997;170:69-80.
38. Robson MC. Exogenous growth factor application effect on human wound healing. Prog Dermatol 1996;30:1-7.
39. Robson MC, Mustoe TA, Hunt TK. The future of recombinant growth factor in wound healing. Am J Surg 1998;176:80S-2S.
40. Grinnell F, Ho C, Wysocki A. Degradation of fibronectin and vitronectin in chronic wound fluid: analysis by cell blotting, immunoblotting and cell adhesion assays. J Invest Dermatol 1992;98:410-6.
41. Wysocki A, Baxter CR, Bergstresser PR, Grinnell F, Horowitz MS, Horowitz B. Topical fibronectin therapy for treatment of a patient with chronic stasis ulcers. Arch Dermatol 1988;124:175-7.